Article info

Download PDFPDF
Randomised controlled trial
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection

Authors

  1. Correspondence to Dr Abhishek Deshpande, Medicine Institute Center for Value-Based Care Research, G10, Cleveland Clinic, Cleveland, OH 44195, USA; abhishekdp{at}gmail.com
View Full Text

Citation

Hassouna H, Deshpande A
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection

Publication history

  • First published July 17, 2017.
Online issue publication 
July 26, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.